Premium
Tretinoin: A review of in vivo pharmacological studies
Author(s) -
Cohen Marvin
Publication year - 1993
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430300406
Subject(s) - tretinoin , acute promyelocytic leukemia , retinoid , in vivo , retinoic acid , pharmacology , medicine , metabolite , retinol , chemistry , biochemistry , biology , vitamin , microbiology and biotechnology , gene
Tretinoin (all‐trans‐retinoic acid), a metabolite of retinol, has shown efficacy in the treatment of acute promyelocytic leukemia. Preclinical studies in rodents indicated that tretinoin inhibited or prevented chemically‐induced skin papillomas or carcinomas. However, tretinoin had no effect on several types of transplantable tumors. Studies of tretinoin's pharmacodynamic profile indicated a lack of central nervous system or cardiovascular activity. Effects of tretinoin on the immune system were dependent on the animal model employed, both enhancement and suppression being reported. Tretinoin appeared to increase serum triglycerides and lower serum as well as liver cholesterol levels. Additional preclinical studies are needed to establish minimal effective doses and quantitation of the time course of changes induced by this retinoid. © 1993 wiley‐Liss, Inc.